Surgery and adjunctive chemotherapy for invasive bladder cancer

Surgical Oncology

Volumn 11, Issue 1-2, 2002, Pages 55-63

  Raghavan, Derek ^a   Quinn, David ^a   Skinner, Donald G ^b   Stein, John P ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adjuvant; Bladder; Carcinoma; Chemotherapy; Neoadjuvant; Transitional

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; HUMAN; MULTIMODALITY CANCER THERAPY; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0036274925     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(02)00007-5     Document Type: Article

References (57)

1. Tumors of the urinary bladder
2. Primary adenocarcinoma of the urinary bladder and urachus
3. Non-transitional cell bladder cancer
4. Clonal analysis of a bladder cancer cell line: An experimental model of tumour heterogeneity
5. Two molecular pathways to transitional cell carcinoma of the bladder
6. Accumulation of nuclear p53 and tumor progression in bladder cancer
7. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer
8. P53 and treatment of bladder cancer
9. Invasive bladder cancer treated with neoadjuvant MVAC: The relationship of p53 nuclear overexpression with survival
10. Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumours
11. Transferrin receptor expression by human bladder transitional cell caricnoma
12. Translational studies of glutathione in bladder cancer cell lines and human specimens
13. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloro-platinum on well established A-431 cell xenografts
14. P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder
15. Review of 150 post-mortems of carcinoma of the urinary bladder
16. Treatment of carcinomatous meningitis from transitional cell carcinoma of the bladder
17. Surgery for invasive bladder cancer
18. Biology and management of invasive bladder cancer
19. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1054 patients
20. Pre-emptive (neo-adjuvant) intravenous chemotherapy for invasive bladder cancer
21. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation
22. Initial intravenous cisplatinum therapy: Improved management for high risk bladder cancer?
23. Cis-diamminedichloro-platinum (II) in locally advanced and metastatic urothelial cancer
24. Neo-adjuvant (preemptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder
25. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase III study
26. Does neoadjuvant cisplatin based chemotherapy improve survival of patients with locally advanced bladder cancer. A meta-analysis of individual patient data from randomized clinical trials
27. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma
28. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors
29. The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: A Northern California Oncology Group study
30. Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen
31. Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: The University of Chicago experience
32. Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival of patients treated with M-VAC with 5-year follow-up
33. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03
34. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial
35. Five year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I
36. SWOG 8710 (INT-0080): Randomized phase III trial of neoadjuvant MVAC+cystectomy versus cystectomy alone in patients with locally advanced bladder cancer
37. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial
38. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy: Results of a controlled prospective study
39. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: Prognostic impact of lymph node involvement
40. A randomized trial of radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer
41. Optimal delivery of perioperative chemotherapy: Preliminary results of a randomized, prospective comparative trial of preoperative and postoperative chemotherapy for invasive bladder cancer
42. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience
43. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group
44. Weekly gemcitabine in advanced bladder cancer: A preliminary report
45. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer
46. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer
47. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma
48. Eastern Cooperative Oncology Group Phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma
49. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma
50. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: The importance of survival as a clinical trial endpoint
51. Phase II trial of combination of paclitaxel and cisplatin in advanced urothelial carcinoma
52. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial
53. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin and cisplatin in patients with advanced transitional-cell carcinoma
54. Paclitaxel, cisplatin and methotrexate in the treatment of refractory urothelial malignancies
55. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group
56. Phase II trial of gemcitabine and cisplatin for metastatic urothelial cancer
57. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study